Outset Medical, Inc. Securities Fraud Lawsuit Update

Investors Urged to Take Lead in OM Lawsuit

LOS ANGELES, Sept. 27, 2024 — Glancy Prongay & Murray LLP (“GPM”) highlights an opportunity for investors facing losses to spearhead the securities fraud class action lawsuit against Outset Medical, Inc. (“Outset Medical” or the “Company”) with the ticker symbol OM.

Class Period: August 1, 2022 – August 7, 2024
Lead Plaintiff Deadline: October 28, 2024

If interested in leading the Outset Medical lawsuit, you can register your contact information at Glancy Prongay’s website. Alternatively, reach out to Charles H. Linehan, of GPM, via phone at 310-201-9150, Toll-Free at 888-773-9224, or through email at shareholders@glancylaw.com for further details.

Allegations and Claims

The complaint suggests that during the Class Period, Defendants concealed vital information from investors about Outset Medical’s Tablo products. Issues included improper marketing for continuous renal replacement therapy, non-FDA approved indications, potential additional applications, sales risks pending FDA approval, insufficient sales infrastructure, adverse revenue growth forecasts, and misleading statements about the Company’s status.

For updates, you can follow Glancy Prongay & Murray LLP on LinkedIn, Twitter, or Facebook.

To be part of the class action, no immediate action is required. You can consult your preferred counsel or remain a passive member. For more details or inquiries, contact Charles Linehan, Esquire, of GPM, at 310-201-9150 or Toll-Free at 888-773-9224, via email at shareholders@glancylaw.com, or by visiting Glancy Prongay’s website.

Note: This press release may be deemed Attorney Advertising in specific jurisdictions as per relevant laws and ethical standards.

Contacts: Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan: 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
Website: www.glancylaw.com